Intratumoral Cancer Therapies Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Checkmate Pharmaceuticals, OncoSec Medical Inc.

DelveInsight’s “Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Intratumoral Cancer Therapies, historical and forecasted epidemiology as well as the Intratumoral Cancer Therapies market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Intratumoral Cancer Therapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Intratumoral Cancer Therapies Market Forecast

Some of the key facts of the Intratumoral Cancer Therapies Market Report: 

• The Intratumoral Cancer Therapies market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• A person’s chance of surviving five years after being diagnosed with cutaneous melanoma improves with earlier diagnosis. Skin melanoma is diagnosed in 81.6% of cases at the local stage, 9% at the regional stage, and 4% at the distant stage when the cancer has spread. Skin-related localised melanoma had a 5-year relative survival rate of 99.5%
• During the prediction period (2021–2022), the United States reported 98,046 instances of melanoma; this number is expected to rise to 2032. In 2021, there were 31,636 cases of melanoma and 91,650 cases of non-melanoma skin cancer (NMSC) in Germany
• Nonmelanoma skin cancer (NMSC), one of the nine primary indications for intratumoral treatments, represented the majority of cases in the 7MM. In 2021, there were 793,007 NMSC instances in the 7MM as a whole
• Key Intratumoral Cancer Therapies Companies: Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Regeneron, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera Pharmaceuticals, Lokon Pharma, Treovir, Immunicum, and others
• Key Intratumoral Cancer Therapies Therapies: Vidutolimod (CMP-001), Tavo (tavokinogene telseplasmid), CAVATAK (V937; CVA21), PVSRIPO (PVS-RIPO), RP1 (vusolimogene oderparepvec), Daromun (Nidlegy), Cotsiranib (STP705), Cavrotolimod (AST-008), INT230-6 (Cisplatin/vinblastine), NanoPac (LSAM paclitaxel), Hensify (NBTXR3/ PEP503), AlloStim, Tasadenoturev (DNX-2401), Tilsotolimod (IMO-2125), Delolimogene mupadenorepvec (LOAd703), G207, Intuvax (Ilixadencel), and others
• The Intratumoral Cancer Therapies market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Intratumoral Cancer Therapies pipeline products will significantly revolutionize the Intratumoral Cancer Therapies market dynamics.

Intratumoral Cancer Therapies Overview

Any treatment that is administered in very close anatomical proximity to a tumour with the goal of direct uptake by tumours or tumour cells is referred to as intratumoral therapy.

The goal of this therapeutic approach is to have the tumour act as its own vaccination. IT immunotherapies aim to start local immune cell recruitment into the tumour microenvironment and then prime T cells for a systemic polyclonal antitumor response (abscopal effect), potentially addressing intra and inter-tumoral heterogeneity. Tumours are used as a source of antigens expressed across multiple tumour clones.

Get a Free sample for the Intratumoral Cancer Therapies Market Report –

https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market

Intratumoral Cancer Therapies Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Intratumoral Cancer Therapies Epidemiology Segmentation:

The Intratumoral Cancer Therapies market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Intratumoral Cancer Therapies
• Prevalent Cases of Intratumoral Cancer Therapies by severity
• Gender-specific Prevalence of Intratumoral Cancer Therapies
• Diagnosed Cases of Episodic and Chronic Intratumoral Cancer Therapies

Download the report to understand which factors are driving Intratumoral Cancer Therapies epidemiology trends @ Intratumoral Cancer Therapies Epidemiology Forecast

Intratumoral Cancer Therapies Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Intratumoral Cancer Therapies market or expected to get launched during the study period. The analysis covers Intratumoral Cancer Therapies market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Intratumoral Cancer Therapies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Intratumoral Cancer Therapies Therapies and Key Companies

• Vidutolimod (CMP-001): Checkmate Pharmaceuticals
• Tavo (tavokinogene telseplasmid): OncoSec Medical Incorporated
• CAVATAK (V937; CVA21): Merck
• PVSRIPO (PVS-RIPO): Istari Oncology
• RP1 (vusolimogene oderparepvec): Replimune/ Regeneron
• Daromun (Nidlegy): Philogen
• Cotsiranib (STP705): Sirnaomics
• Cavrotolimod (AST-008): Exicure
• INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
• NanoPac (LSAM paclitaxel): NanOlogy
• Hensify (NBTXR3/ PEP503): Nanobiotix
• AlloStim: Immunovative Therapies
• Tasadenoturev (DNX-2401): DNAtrix
• Tilsotolimod (IMO-2125): Idera Pharmaceuticals
• Delolimogene mupadenorepvec (LOAd703): Lokon Pharma
• G207: Treovir
• Intuvax (Ilixadencel): Immunicum

Discover more about therapies set to grab major Intratumoral Cancer Therapies market share @ Intratumoral Cancer Therapies Treatment Market

Scope of the Intratumoral Cancer Therapies Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Intratumoral Cancer Therapies Companies: Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Regeneron, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera Pharmaceuticals, Lokon Pharma, Treovir, Immunicum, and others
• Key Intratumoral Cancer Therapies Therapies: Vidutolimod (CMP-001), Tavo (tavokinogene telseplasmid), CAVATAK (V937; CVA21), PVSRIPO (PVS-RIPO), RP1 (vusolimogene oderparepvec), Daromun (Nidlegy), Cotsiranib (STP705), Cavrotolimod (AST-008), INT230-6 (Cisplatin/vinblastine), NanoPac (LSAM paclitaxel), Hensify (NBTXR3/ PEP503), AlloStim, Tasadenoturev (DNX-2401), Tilsotolimod (IMO-2125), Delolimogene mupadenorepvec (LOAd703), G207, Intuvax (Ilixadencel), and others
• Intratumoral Cancer Therapies Therapeutic Assessment: Intratumoral Cancer Therapies current marketed and Intratumoral Cancer Therapies emerging therapies
• Intratumoral Cancer Therapies Market Dynamics: Intratumoral Cancer Therapies market drivers and Intratumoral Cancer Therapies market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Intratumoral Cancer Therapies Unmet Needs, KOL’s views, Analyst’s views, Intratumoral Cancer Therapies Market Access and Reimbursement 

To know more about Intratumoral Cancer Therapies companies working in the treatment market, visit @ Intratumoral Cancer Therapies Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Intratumoral Cancer Therapies Market Report Introduction

2. Executive Summary for Intratumoral Cancer Therapies

3. SWOT analysis of Intratumoral Cancer Therapies

4. Intratumoral Cancer Therapies Patient Share (%) Overview at a Glance

5. Intratumoral Cancer Therapies Market Overview at a Glance

6. Intratumoral Cancer Therapies Disease Background and Overview

7. Intratumoral Cancer Therapies Epidemiology and Patient Population

8. Country-Specific Patient Population of Intratumoral Cancer Therapies 

9. Intratumoral Cancer Therapies Current Treatment and Medical Practices

10. Intratumoral Cancer Therapies Unmet Needs

11. Intratumoral Cancer Therapies Emerging Therapies

12. Intratumoral Cancer Therapies Market Outlook

13. Country-Wise Intratumoral Cancer Therapies Market Analysis (2019–2032)

14. Intratumoral Cancer Therapies Market Access and Reimbursement of Therapies

15. Intratumoral Cancer Therapies Market Drivers

16. Intratumoral Cancer Therapies Market Barriers

17.  Intratumoral Cancer Therapies Appendix

18. Intratumoral Cancer Therapies Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services